BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Sirnaomics Completes IND-Enabling Studies for siRNA Therapeutic STP125G Targeting ApoC3

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”),...

July 24, 2024 | News

Waters Launches High-Throughput RS-DSC for Biologics Stability Testing

Reduces sample volume requirements by 25x through use of advanced microfluidic technologies while increasing throughput up to 24x compared with competito...

July 24, 2024 | News

Agilent Acquires BIOVECTRA for $925 Million, Expanding Biopharma Capabilities

Agilent Technologies Inc. announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing...

July 23, 2024 | News

Rona Therapeutics Secures $35 Million Series A+ Financing to Advance siRNA Programs

Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 M...

July 22, 2024 | News

Sanyou Bio and Huadong Medicine Advance SYHD001 ADC Drug to Phase I Clinical Trials

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration wi...

July 17, 2024 | News

Biosyngen's Groundbreaking CAR-T Therapy BRG01 Approved for Phase II Clinical Trial in China

Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation ...

July 17, 2024 | News

Merck Life Science Launches First GMP Compliant Manufacturing Line for Cell Culture Media in China

Merck Life Science is thrilled to announce the commencement of commercial production at our first Good Manufacturing Practice (GMP) compliant manuf...

July 16, 2024 | News

Nona Biosciences and Alaya.bio Announce Collaboration to Revolutionize CAR-T Cell Therapy Development

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody disc...

July 15, 2024 | News

ADM Korea to Submit IND for Niclosamide-Based Combination Therapy for Prostate Cancer

IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metab...

July 12, 2024 | News

National Cancer Center and University of Pennsylvania License CCR4 CAR-T Cell Therapy to ARC Therapies Inc.

The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a ch...

July 12, 2024 | News

A*STAR and SingHealth Collaborate on SGD$18 Million TISHUMAP Project to Transform Drug Discovery in Asia

A*STAR’s Genome Institute of Singapore (GIS) has secured nearly SGD$18 million to develop an innovative data platform, TISHUMAP1. This platform is se...

July 09, 2024 | News

MGI Australia Partners with University of Queensland to Combat Antimicrobial Resistance

MGI Australia Pty Ltd, subsidiary of MGI Tech Co., Ltd., a company committed to building core tools and technologies that drive innovation in life science,...

July 09, 2024 | News

Immorna Biotherapeutics to Launch Phase 1/2 Study of Novel mRNA Therapeutic for Cancer

Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics a...

July 09, 2024 | News

Sirnaomics Announces Positive Interim Results for Phase I Clinical Study of RNAi Therapeutic STP122G Targeting Factor XI

Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engagin...

July 09, 2024 | News

Stay Connected